Edition:
India

Obseva SA (OBSV.OQ)

OBSV.OQ on NASDAQ Stock Exchange Global Select Market

9.80USD
15 Dec 2017
Change (% chg)

$0.03 (+0.31%)
Prev Close
$9.77
Open
$9.92
Day's High
$9.92
Day's Low
$9.78
Volume
15,731
Avg. Vol
7,965
52-wk High
$14.18
52-wk Low
$5.02

Chart for

About

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor... (more)

Overall

Beta: --
Market Cap(Mil.): $257.50
Shares Outstanding(Mil.): 29.63
Dividend: --
Yield (%): --

Financials

BRIEF-Obseva Initiates Phase 2A Clinical Trial Of Obe022 In Preterm Labor

* OBSEVA INITIATES PROLONG, THE PHASE 2A CLINICAL TRIAL OF OBE022 IN PRETERM LABOR

05 Dec 2017

BRIEF-ObsEva SA files for resale of up to 7.5 million common shares‍​

* ObsEva SA - files for resale of up to 7.5 million common shares‍​ of co by the selling shareholders - SEC filing Source text: (http://reut.rs/2yMfBxk) Further company coverage:

10 Nov 2017

BRIEF-ObsEva SA announces $60 mln private placement with existing and new investors

* ObsEva SA announces $60.0 million private placement with existing and new investors

10 Oct 2017

BRIEF-Obseva announces completion of patient recruitment

* Obseva SA announces the completion of patient recruitment in the implant2 phase 3 clinical trial in assisted reproductive technology ahead of schedule

06 Sep 2017

BRIEF-Medicxi Growth I GP limited reports a 5.30 percent passive stake in ‍obseva Sa as of August 22 2017 - SEC filing​

* Medicxi Growth I GP limited reports a 5.30 percent passive stake in ‍obseva SA as of August 22 2017 - SEC filing​ Source text - http://bit.ly/2x97A3E Further company coverage:

31 Aug 2017

BRIEF-ObsEva Q2 loss per share $0.61

* ObsEva reports second quarter 2017 financial results and provides business update

16 Aug 2017

Earnings vs. Estimates